Hsin-Chu, Taiwan

Shu-Lin Chang


Average Co-Inventor Count = 3.2

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Hsin-Chu, JP (2010)
  • Hsin-Chu, TW (2008 - 2011)

Company Filing History:


Years Active: 2008-2011

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Shu-Lin Chang

Introduction

Shu-Lin Chang is a notable inventor based in Hsin-Chu, Taiwan. He has made significant contributions to the field of immunology, particularly through his innovative patents. With a total of 3 patents, his work focuses on methods for treating various Th1-mediated disorders.

Latest Patents

One of his latest patents describes a method of treating a Th1-mediated disorder. This method includes administering to a subject in need of treatment an effective amount of a compound of a specific formula. The formula includes various components where R can be H, alkyl, aryl, or cyclyl, and other variables define the structure of the compound. The Th1-mediated disorders targeted by this invention include non-obese diabetes, Crohn's colitis, autoimmune hemolytic anemia, rheumatoid arthritis, autoimmune encephalitis, multiple sclerosis, and autoimmune myocarditis. Additionally, he has developed immunomodulatory compositions that are useful for identifying plant compositions with immunomodulatory activity. These compositions are particularly beneficial for increasing immune responses, such as IFN-γ or IL-2 transcription.

Career Highlights

Shu-Lin Chang is affiliated with Academia Sinica, a prestigious research institution in Taiwan. His work has been instrumental in advancing the understanding and treatment of autoimmune disorders through innovative pharmaceutical compositions.

Collaborations

He has collaborated with notable colleagues, including Wen-Chin Yang and Yi-Ming Chiang, to further enhance the impact of his research.

Conclusion

Shu-Lin Chang's contributions to immunology through his patents and collaborations highlight his role as a significant inventor in the field. His innovative approaches to treating Th1-mediated disorders continue to pave the way for advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…